A randomised phase III trial of focal fractionated conformal stereotactic boost following conventional radiotherapy of high grade gliomas

ISRCTN ISRCTN37123666
DOI https://doi.org/10.1186/ISRCTN37123666
ClinicalTrials.gov number NCT00003916
Secondary identifying numbers E164/8 (BR10)
Submission date
06/04/2000
Registration date
06/04/2000
Last edited
20/09/2017
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Miss Sally Stenning
Scientific

MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Email ss@ctu.mrc.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Scientific titleA randomised phase III trial of focal fractionated conformal stereotactic boost following conventional radiotherapy of high grade gliomas
Study objectivesTo determine the effect of a stereotactic boost of radiotherapy on the survival time of patients with high-grade gliomas.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedCancer
InterventionThe trial is designed to randomise patients between two treatment arms:
1. Conventional radiotherapy
2. Conventional radiotherapy plus a stereotactic boost
Intervention typeOther
Primary outcome measureSurvival and quality of life.
Secondary outcome measuresNot provided at time of registration
Overall study start date01/04/1999
Completion date07/12/2001

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
Upper age limit65 Years
SexNot Specified
Target number of participants605
Key inclusion criteria1. Histologically confirmed gliomas World Health Organisation (WHO) III/IV, no previous histology of low grade tumours WHO I/II
2. Tumour volumes less than 4.0 cm
3. No tumours in brain stem or infratentorial location, no multifocal gliomas
4. Ability to treat tumour safely by stereotactic radiotherapy
5. Eastern Cooperative Oncology Group (ECOG)/World Health Organisation (WHO) performance status 0-2
6. Patient able to tolerate full course of conventional radiotherapy
7. Prior neurosurgery within 6 weeks of randomisation
8. Aged greater than 18 and less than 65 years
9. Informed consent
10. No prior chemo- or radiotherapy
Key exclusion criteriaNot provided at time of registration
Date of first enrolment01/04/1999
Date of final enrolment07/12/2001

Locations

Countries of recruitment

  • Australia
  • England
  • France
  • Germany
  • Netherlands
  • Spain
  • Switzerland
  • United Kingdom

Study participating centre

MRC Clinical Trials Unit
London
NW1 2DA
United Kingdom

Sponsor information

Medical Research Council (MRC) (UK)
Research council

20 Park Crescent
London
W1B 1AL
United Kingdom

Phone +44 (0)20 7636 5422
Email clinical.trial@headoffice.mrc.ac.uk
Website http://www.mrc.ac.uk

Funders

Funder type

Research council

Medical Research Council (MRC) (UK)
Government organisation / National government
Alternative name(s)
Medical Research Council (United Kingdom), UK Medical Research Council, MRC
Location
United Kingdom

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Other publications article 01/04/1999 Yes No
Results article results 01/08/2008 Yes No

Editorial Notes

20/09/2017: Publication reference added.